Stefano Scorza
Cagliari, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study.
Journal: Intestinal research
Published: April 29, 2025
Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study.
Journal: Journal of clinical medicine
Published: September 23, 2024
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study.
Journal: Expert opinion on pharmacotherapy
Published: June 26, 2023
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study.
Journal: Expert opinion on biological therapy
Published: February 27, 2023
Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients.
Journal: European journal of gastroenterology & hepatology
Published: March 20, 2021
Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn's disease: results from a large Italian cohort study.
Journal: European review for medical and pharmacological sciences
Published: March 04, 2021
Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers.
Journal: European journal of internal medicine
Published: March 19, 2019
Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers.
Journal: Medicine
Published: August 26, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026